ATXS
Astria Therapeutics Inc

11,118
Loading...
Loading...
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
78

Frequently Asked Questions

What is Market Cap of Astria Therapeutics Inc?
What is the 52-week high for Astria Therapeutics Inc?
What is the 52-week low for Astria Therapeutics Inc?
What is Astria Therapeutics Inc stock price today?
What was Astria Therapeutics Inc stock price yesterday?
What is the PE ratio of Astria Therapeutics Inc?
What is the Price-to-Book ratio of Astria Therapeutics Inc?
What is the 50-day moving average of Astria Therapeutics Inc?
How many employess does Astria Therapeutics Inc has?

Latest ATXS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.